---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Clinical presentation - signs and symptoms. Topics: Age-dependent presentation: visceral in infancy, neurological from late infancy onward; Hepatic and visceral symptoms: neonatal cholestasis and hepatosplenomegaly in the pre/perinatal period; Hepatic and visceral symptoms: frequency of splenomegaly, hepatomegaly, and neonatal jaundice in the International Niemann-Pick Disease Registry; Hepatic and visceral symptoms: neonatal liver disease and earlier neurological onset in 93 individuals with NPC1; 14 further topics. 18 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Age-dependent presentation: visceral in infancy, neurological from late infancy onward

> “Niemann-Pick disease type C (NPC) is a slowly progressive lysosomal disorder whose principal manifestations are age dependent.”
> “The manifestations in the perinatal period and infancy are predominantly visceral, with hepatosplenomegaly, cholestatic jaundice, and (in some instances) pulmonary infiltrates.”
> “From late infancy onward, the presentation is dominated by neurologic manifestations.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-2"></a>

### Hepatic and visceral symptoms: neonatal cholestasis and hepatosplenomegaly in the pre/perinatal period

> “Statement #4: NPC primarily manifests in the pre/perinatal age group as liver disease presenting with prolonged cholestatic jaundice, hepatosplenomegaly, and in some cases fetal hydrops or ascites and acute liver failure, with or without pulmonary disease.”
> “In most cases, jaundice resolves spontaneously by 3–4 months of age, while organomegaly persists to variable degrees.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.6-3"></a>

### Hepatic and visceral symptoms: frequency of splenomegaly, hepatomegaly, and neonatal jaundice in the International Niemann-Pick Disease Registry

> “Here we report NPC patient data from the International Niemann-Pick Disease Registry (INPDR).”
> “The proportion of patients who developed splenomegaly was 72.8%, whilst hepatomegaly was reported in 39.5% of patients.”
> “Similarly, neonatal jaundice was noted in 39.5% of patients, and hepatic failure in the neonatal period was 6.2%.”
> “The proportion of patients with neonatal jaundice, spleno- and hepatomegaly decreased with increasing age of neurological onset.”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.6-4"></a>

### Hepatic and visceral symptoms: neonatal liver disease and earlier neurological onset in 93 individuals with NPC1

> “Liver disease was characterized in 93 individuals with NPC1 using FibroScan, abdominal ultrasound, and plasma liver function tests at baseline and longitudinally over up to a four-year period.”
> “Those with no history of neonatal liver disease had an average age of 10.3 years at time of neurological symptoms, compared to 5.9 years for those with mild/moderate disease and 3.6 years for those with severe disease (p = 0.002).”

Source: [Agrawal et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12818573/)

<a id="topic-2.2.1.6-5"></a>

### Respiratory symptoms: pulmonary foam-cell infiltration in infancy

> “Infiltration of the lungs with foam cells may accompany neonatal liver disease or occur as a primary presenting feature (pulmonary failure secondary to impaired gas exchange).”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-6"></a>

### Motor and developmental symptoms: hypotonia and delayed motor milestones in early infantile onset

> “Statement #5: Hypotonia and delay in developmental motor milestones characterize the neurological manifestation of NPC in early infancy. Hepatosplenomegaly and/or prolonged neonatal jaundice are almost invariably noted, although cases with severe hypotonia in early infancy without obvious visceral disease can occur. Pulmonary disease may also be present.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.6-7"></a>

### Motor and developmental symptoms: early infantile onset in a French cohort

> “Data available on all NP-C patients with early infantile neurological onset diagnosed in France between 1990 and 2013 were compiled.”
> “All patients in the present EI-NP-C series began neurological symptoms before 18 months of age”
> “only few patients temporarily acquired autonomous walking, and none did acquire a fully normal gait.”
> “Hypotonia and motor development delay were the first neurological sign in 85% of the patients, ataxia, and psychomotor regression in the remaining 15%.”

Source: [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/)

<a id="topic-2.2.1.6-8"></a>

### Motor and developmental symptoms: clumsiness, gait disturbance, and speech delay in late infantile onset

> “Statement #6: Clumsiness, gait disturbance, and fine motor skill impairments characterize this age of disease onset. Speech delay, a history of neonatal cholestasis, seizures, pulmonary disease, variable visceromegaly, and failure to reach or loss of developmental milestones may be noted.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.6-9"></a>

### Motor and developmental symptoms: developmental milestone delay by age at neurological onset in the registry

> “Of the 46 patients where data is available, the most common manifestations were delay/impairments in: cognition (69.6%), speech (60.9%), motor (60.9%) and social (45.7%).”
> “In respect to neurological classification, speech delay was most common in early infantile (91.7%), whilst cognitive impairment was most common in late infantile (78.9%) and adult (100%), with motor delay (33.3%) and cognitive impairment (33.3%) predominant in juvenile onset.”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.6-10"></a>

### Neurological symptoms: frequency of neurological manifestations in the registry

> “The most common neurological manifestations reported include cognitive impairment (78.5%), dysarthria (75.9%), ataxia (75.9%), vertical supranuclear gaze palsy (VSGP) (70.9%), dysphagia (69.6%), dystonia (53.2%), seizures (48.1%), and cataplexy (35.4%).”
> “Overall, the late infantile onset subgroup made up the highest proportion of neurological manifestations, with the exception of psychiatric manifestations and cognitive impairment.”
> “The least prevalent neurological manifestations were psychiatric manifestations (13.9%) and hearing impairment (7.6%).”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.6-11"></a>

### Oculomotor symptoms: vertical supranuclear saccadic palsy and gaze palsy

> “Vertical supranuclear saccadic palsy (VSSP), followed later by vertical supranuclear gaze palsy (VSGP), is typically present but often unrecognized.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

> “Children compensate for the oculomotor deficits with blinks and head / upper body movements that represent a diagnostic clue for this disease.”
> “VSSP first manifests as decreased velocity of vertical saccades, gradually slowing down and eventually lost, resulting in restricted range of vertical eye movements, or VSGP.”
> “In late stages of the illness, horizontal saccades are also impaired.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-12"></a>

### Seizures and gelastic cataplexy

> “Approximately one third of individuals with NPC have partial and/or generalized seizures.”
> “Epilepsy may be refractory to medical therapy in some.”
> “About 20% of children with NPC have gelastic cataplexy, a sudden loss of muscle tone evoked by a strong emotional (humorous) stimulus.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-13"></a>

### Seizures and gelastic cataplexy: early infantile onset

> “During the later course of disease, about half of the patients developed seizures, and approximately one fourth gelastic cataplexy.”

Source: [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/)

<a id="topic-2.2.1.6-14"></a>

### Movement disorder and bulbar symptoms: dystonia, dysarthria, and dysphagia

> “In addition to the manifestations above, many children develop dystonia, typically beginning as action dystonia in one limb that gradually spreads to involve all limbs and axial muscles.”
> “Speech gradually deteriorates, with a mixed dysarthria and dysphonia.”
> “Dysphagia progresses in parallel with the dysarthria, and oral feeding eventually becomes impossible.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-15"></a>

### Auditory symptoms: hearing loss in 50 patients with NPC1

> “Data from 50 patients with NPC1 confirm a prevalent, often high frequency, hearing loss that is progressive in at least some individuals.”
> “Retrocochlear involvement is common, and some patients present with a profile of auditory neuropathy spectrum disorder.”
> “Moreover, of the 31 patients with behavioral data, 23 (74%) presented with clinically significant hearing loss involving the frequencies most important to speech understanding (500–4000 Hz).”

Source: [King et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3895917/)

<a id="topic-2.2.1.6-16"></a>

### Auditory symptoms: sensory deafness as a first symptom in late infantile onset

> “The first symptoms may be gelastic cataplexy (sometimes associated with narcolepsy) or sensory deafness.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.6-17"></a>

### Cognitive symptoms: progressive cognitive impairment in childhood

> “These physical manifestations are accompanied by insidiously progressive cognitive impairment, often mistaken at first for simple learning disability.”
> “As the disease progresses, it becomes clear that the child is mentally deteriorating.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-18"></a>

### Cognitive and psychiatric symptoms: juvenile and adult onset

> “Statement #7: Juvenile onset manifests as cognitive impairment (lagging behind peers in school, language and learning difficulties), coordination problems (clumsiness, frequent falls, progressive ataxia, and dystonia), seizures, and VSGP.”
> “Cognitive impairment invariably occurs and tends to present with higher rates of psychiatric illness alongside neurological manifestations.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
